This research aims to investigate the relationship between virus seropositivity and the occurrence of erectile dysfunction (ED). We obtained data from the U.S. Centers for Disease Control and Prevention's National health and nutrition examination survey regarding ED, hepatitis A, herpes simplex virus type 1, herpes simplex virus type 2, and cytomegalovirus, along with sociodemographic variables. We then evaluated the associations between ED and viral exposure using adjusted multivariable models. A total of 3184 participants were included in the subsequent analysis. In this study, males with ED were found to have lower levels of education, were married or living with partner, belonged to a lower socio-economic status, had a less physically active lifestyle, were smokers, and also had diabetes (all with a significance of P < .05). Our study investigating the relationship between Hepatitis A seropositivity and ED found that patients with Hepatitis A seropositivity had a higher likelihood of experiencing ED. This link remained statistically significant even when accounting for various other factors (odds ratio [OR] = 1.98; 95% confidence interval [CI] = 1.65-2.36; P < .0001). Additionally, we found that exposure to cytomegalovirus (CMV), determined by the presence of anti-CMV IgG antibodies, was also associated with ED (OR = 1.47; 95% CI = 1.14-2.25; P = .0329). This relationship remained significant after accounting for various covariates. In contrast, no associations were found between ED and seropositivity for herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) in the sample (all P values < 0.05). This study found that seropositivity for Hepatitis A or CMV is associated with ED.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835075 | PMC |
http://dx.doi.org/10.1097/MD.0000000000041355 | DOI Listing |
JAMA Netw Open
March 2025
Exercise Medicine Research Institute, Edith Cowan University, Perth, Australia.
Importance: Sexual dysfunction is a common adverse effect of prostate cancer treatment, and current management strategies do not adequately address physical and psychological causes. Exercise is a potential therapy in the management of sexual dysfunction.
Objective: To investigate the effects of supervised, clinic-based, resistance and aerobic exercise with and without a brief psychosexual education and self-management intervention (PESM) on sexual function in men with prostate cancer compared with usual care.
Sex Med Rev
March 2025
Department of Urology, University of Texas MD Anderson Cancer Center and McGovern Medical School at Houston, Houston, 77030, TX, United States.
Introduction: Penile prosthesis (PP) is one of the main approved therapies for erectile dysfunction (ED). Greater than 50 years of clinical use has led to considerable innovation in PP surgery and patient care.
Objectives: To summarize the current literature and provide updated clinical evidence to inform healthcare providers on best practices with PP.
BMC Urol
March 2025
Energy Systems Engineering Department, Engineering Faculty, Adana Alparslan Türkeş Science and Technology University, Adana, 01250, Türkiye.
Erectile dysfunction (ED) is a urological condition defined as the inability of a man to achieve or maintain an erection. This condition negatively affects his sexual performance and the performance of his partner. Phosphodiesterase type 5 (PDE5) inhibitors are commonly used to treat ED.
View Article and Find Full Text PDFExpert Opin Pharmacother
March 2025
Jumeirah American Clinic, Dubai, UAE.
Introduction: Erectile dysfunction (ED) pathophysiology involves complex interactions between vasculogenic, hormonal, and neurological mechanisms, with endothelial dysfunction and oxidative stress playing crucial roles. There is growing interest in intravenous (IV) peptides and amino acids as potential therapeutic options for ED treatment.
Areas Covered: This narrative review examines recent developments in peptide and amino acid therapies for ED, focusing on PT-141, PnPP-19, L-arginine, and L-citrulline.
J Ethnopharmacol
March 2025
Department of Biochemistry, Faculty of Science, Ekiti State University, Ekiti State, Nigeria. Electronic address:
Ethnopharmacological Relevance: Sphenocentrum jollyanum (Pierre) is a medicinal plant native to West African countries, especially Nigeria and Ghana. The leaf of S. jollyanum is a traditional therapy for diabetes, erectile dysfunction, gastrointestinal disorders, and malaria.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!